Sentinel Lymph Node Biopsy in Early Breast Cancer: a Real-world Multicenter Cross-sectional Study (CABS001 Study)

Sentinel Lymph Node Biopsy in Early Breast Cancer: a Real-world Multicenter Cross-sectional Study (CABS001 Study)

Objective: To investigate the current clinical practice of sentinel lymph node biopsy (SLNB) in patients with early stage breast cancer in China. Methods: The data of early breast cancer patients who underwent SLNB in 40 Grade III Level A hospitals in China in 2018 will be collected. Different centers, tracer methods, molecular typing and neoadjuvant chemotherapy will be used as stratification factors to analyze the implementation rate, number of detections, positive rate of SLNB and the follow-up treatment.

Inclusion Criteria:

• breast cancer confirmed by fine needle aspiration or biopsy
• SLNB with or without axillary lymph node dissection
• receiving conventional systematic treatment or regional treatment
• complete medical record.

Exclusion Criteria:

• IV stage breast cancer
• combined with secondary invasive malignant tumor
• diagnosed with other serious disease, including congestive heart failure (NYHA cardiac function grade II, III, IV) or congestive heart failure, unstable angina pectoris, myocardial infarction, high-risk uncontrollable heart rate disorder or other serious cardiovascular diseases within 6 months
• difficulty breathing at rest or need oxygen therapy
• severe infection
• uncontrolled diabetes
• serious psychological or mental disorders
• poor compliance.